Baseline Edmonton Symptom Assessment System and survival in metastatic renal cell carcinoma.

Autor: Graham, J.^1,2, Gingerich, J.^1,2, Lambert, P.², Alamri, A.³, Czaykowski, P.^1,2 pczaykowski@cancercare.mb.ca

Publikováno v: Current Oncology. Aug2018, Vol. 25 Issue 4, pe319-e323. 5p. 4 Charts, 3 Graphs.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

Autor: Fizazi, Karim, Tran, Namphuong, Fein, Luis, Matsubara, Nobuaki, Rodriguez Antolin, Alfredo, Alekseev, Boris Y., Özgã¼roglu, Mustafa, Dingwei, Ye, Feyerabend, Susan, Protheroe, Andrew, De Porre, Peter, Kheoh, Thian, Park, Youn C., Todd, Mary B., Chi, Korbenfeld E, Kim N., Metrebian, S, Kaen, L, Staneloni, E, Batagelj, E, Tan, H, Hovey, E, Woo, H, Frydenberg, M, Chua, W, D’Hondt, L, Evaraert, E, Verschaeve, V, Wynendaele, W, Schrijvers, D, Waltregny, D, Whenham, N, Demey, W, Franke, F, Panhoca, R, Damião, R, Zucca, L, Da Rosa, V, Reis, R, Scalabrini, A, Nahas, W, Girotto, G, Nogueira, A, Gomes, A, Coradazzi, A, Kurteva, G, Siemens, R, Gingerich, J, Fleshner, N, Fradet, Y, Morgan, S, North, S, Saad, F, Shayegan, B, Zalewski, P, Pinochet, R, Orellana, N, Ding, Q, Ye, Z, Xie, L, Du, C, Chen, Z, Huang, Y, Sun, Z, Li, H, Jin, J, Li, C, Wan, B, Tian, Y, Zhou, F, Xie, K, Yao, X, Qiu, M, Zou, Q, Na, Y, Sun, Y, Xue, B, Ma, L, Martinez, C, Salazar, M, Larios, C, Solano, S, Pavlik, I, Brodak, M, Hora, M, Büchler, T, Borre, M, Johansen, J, Mejlholm, I, Poulsen, M, Wittendorf, He, Tammela, T, Vaarala, M, Theodore, C, Staudacher, L, Villers, A, Laplaige, P, Suttman, H, Steuber, T, Natale, S, Jones, R, Tran, A, Mazhar, D, Mills, J, Nyirady, P, Salamon, C, Torzsok, F, Feher, J, Géczi, L, Lakatos, A, Keizman, D, Sella, A, Frank, S, Peer, A, Rosenbaum, E, Berger, R, Mermershtain, W, Carteni, G, Tonini, G, De Giorgi, U, Facchini, G, Berruti, Alfredo, Bracarda, S, Basso, U, Galli, L, Tortora, G, Alietta, M, Fukasawa, S, Suzuki, H, Hasumi, H, Tsuchiya, T, Uemura, H, Kanayama, H, Hashine, K, Sato, F, Matsumoto, H, Oya, M, Lee, Jl, Park, S, Keam, B, Yun, H, Kim, Y, Kang, B, Lee, K, Kim, C, Saad, M, Sundram, M, Calvo, D, Moreno, R, Rodriquez, J, Hernandez, C, van den Berg, H, De La Rosett, J, Van Moorse, R, Hunting, J, Hendriks, M, Kueppers, F, Gilling, P, Beaven, A, Holmes, M, Jassem, J, Oszukowska, E, Niezabitowski, J, Jaxa Larecka, D, Chwalinski, M, Swiniarski, P, Silva, C, Conceicãoa, P, Fraga, A, Mauricio, J, Rodrigues, T, Pinheiro, L, Lima, E, Palma Dos Reis, J, Volovat, C, Jinga, V, Harza, M, Alyasova, A, Budnik, N, Bychkov, Y, Izmaylov, A, Khvorosten, D, Matveev, V, Novsov, A, Vladimirov, V, Tevs, D, Sheveleva, L, Bulanov, A, Semenov, A, Fadeeva, N, Kulikov, E, Emelyanov, S, Karyakin, O, Shirinkin, V, Shkolnik, M, Lykov, A, Skopin, P, Kopyltsov, E, Mincik, I, Mir, O, Kliment, J, Mikurcik, E, Gajdos, M, Milichovsky, I, Malan, J, Bahlmann, J, Moshokoa, E, Madlala, T, Coetzee, L, Ribal, M, Miñana, B, Martinez Breijo, S, Carballido, J, Olmos, D, Requena, M, Morote, J, Damber, Je, Haggman, M, Nyman, C, Ljungberg, B, Bjartell, A, Ozen, H, Beduk, Y, Sozen, S, Cetinkaya, M, Ozyurt, M, Tansug, Z, Mungan, A, Tanidir, Y, Toktas, M, Hotko, E, Stus, V, Lyulko, O, Vinnyk, Y, Shparyk, Y, Sakalo, V, Bondarenko, I, Paramonov, V, Khareba, G, Hodos, V.

Publikováno v: The New England journal of medicine, Vol. 377, no. 4, p. 352-360 (2017)

Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus prednisone is indicated for metastatic castration-resistant prostate cancer. We evaluated the clinical benefit of abiraterone acetate plus prednisone with androgen-deprivatio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1802294eaa5a930bead58e33d28c57b6
https://doi.org/10.1056/nejmoa1704174

LBA51 - CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC)

Autor: Hotte, S.J. ¹, Winquist, E. ², Chi, K.N. ³, Ellard, S.L. ⁴, Sridhar, S. ⁵, Emmenegger, U. ⁶, Salim, M. ⁷, Iqbal, N.N. ⁸, Canil, C. ⁹, Kollmannsberger, C.K. ³, Hansen, A.R. ¹⁰, Lalani, A-K A ¹, Gingerich, J. ¹¹, Finch, D. ⁴, Cabanero, M. ¹², Wyatt, A.W. ¹³, Tu, D. ¹⁴, Vera-Badillo, F. ¹⁵, Seymour, L.K. ¹⁶, Smoragiewicz, M. ¹⁵

Publikováno v: In Annals of Oncology October 2019 30 Supplement 5:v885-v885

Targeting the EGFR pathway for cancer therapy

Autor: Johnston, JB, Navaratnam, S, Pitz, MW, Maniate, JM, Wiechec, Emilia, Baust, H, Gingerich, J, Skliris, GP, Murphy, LC, Los, M

Publikováno v: Johnston, JB, Navaratnam, S, Pitz, MW, Maniate, JM, Wiechec, E, Baust, H, Gingerich, J, Skliris, GP, Murphy, LC & Los, M 2006, ' Targeting the EGFR pathway for cancer therapy ', Curr Med Chem, vol. 13(29), pp. 3483-92 .

Clinical studies have shown that HER-2/Neu is over-expressed in up to one-third of patients with a variety of cancers, including B-cell acute lymphoblastic leukemia (B-ALL), breast cancer and lung cancer, and that these patients are frequently resist

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pure_au_____::2e67b3d9272b74c7a79fb6e4a236e0a6
https://pure.au.dk/portal/da/publications/targeting-the-egfr-pathway-for-cancer-therapy(8e5fb9f0-ef72-11db-bee9-02004c4f4f50).html